Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice
- PMID: 10751036
- DOI: 10.1023/a:1007573531947
Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice
Abstract
Purpose: To study the contribution of P-glycoprotein (P-gp) to the oral absorption of a substrate, tacrolimus, by comparing the extent and rate of bioavailability in normal and mdr1a knockout mice. Methods. Intravenous and oral (2 mg/kg) blood concentration data of tacrolimus in normal and knockout mice were obtained from a study by K. Yokogawa et al. in Pharm. Res. 16:1213-1218 (1999). Mean bioavailability (F), mean hepatic first-pass extraction ratio (Fh), mean bioavailability rates, mean oral clearance, and mean total hepatic intrinsic clearance were calculated using standard pharmacokinetic methods.
Results: The mean F of tacrolimus (an apparently highly permeable compound) was increased from 0.22 in normal mice to 0.72 in knockout mice. These values were consistent with mean predicted Eh (based on intravenous data) of 0.77 and 0.27 in normal and knockout mice, respectively. Great similarity in the relative bioavailability profile (such as short Tmax) between normal and knockout mice was also found. Mean oral clearance and mean total or unbound hepatic intrinsic clearance of tacrolimus in knockout mice were found to be about 10 times lower compared to those in normal mice.
Conclusions: The above results suggest an apparent lack of effect of P-gp on the gastrointestinal absorption of tacrolimus in normal mice under the study condition. It is postulated that the effect of P-gp on the rate and extent of oral absorption should be more pronounced for those more slowly or incompletely absorbed drugs (i.e., drugs with relatively low permeabilities) as illustrated by talinolol in humans. The clearance data also suggest a very dominant role of P-glycoprotein in controlling the rate of hepatic metabolism of tacrolimus in normal mice, and P-glycoprotein may serve as an effective efflux pump for direct transport of metabolites formed in hepatocytes into the blood circulation.
Similar articles
-
P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice.Pharm Res. 1999 Aug;16(8):1213-8. doi: 10.1023/a:1018993312773. Pharm Res. 1999. PMID: 10468022
-
Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats.J Pharm Sci. 2002 Mar;91(3):719-29. doi: 10.1002/jps.10041. J Pharm Sci. 2002. PMID: 11920757
-
Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.J Pharmacol Exp Ther. 2001 May;297(2):547-55. J Pharmacol Exp Ther. 2001. PMID: 11303042
-
Modulation of oral bioavailability of anticancer drugs: from mouse to man.Eur J Pharm Sci. 2000 Dec;12(2):103-10. doi: 10.1016/s0928-0987(00)00153-6. Eur J Pharm Sci. 2000. PMID: 11102737 Review.
-
Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.Am J Health Syst Pharm. 2006 Dec 1;63(23):2340-8. doi: 10.2146/ajhp060080. Am J Health Syst Pharm. 2006. PMID: 17106006 Review.
Cited by
-
The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. AAPS J. 2009. PMID: 19319690 Free PMC article.
-
Coexistence of passive and carrier-mediated processes in drug transport.Nat Rev Drug Discov. 2010 Aug;9(8):597-614. doi: 10.1038/nrd3187. Nat Rev Drug Discov. 2010. PMID: 20671764 Review.
-
Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model.Pharm Res. 2001 Apr;18(4):544-7. doi: 10.1023/a:1011022931368. Pharm Res. 2001. PMID: 11451044 No abstract available.
-
Theoretical predictions of drug absorption in drug discovery and development.Clin Pharmacokinet. 2002;41(11):877-99. doi: 10.2165/00003088-200241110-00005. Clin Pharmacokinet. 2002. PMID: 12190333 Review.
-
Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs.Pharm Res. 2001 Dec;18(12):1721-8. doi: 10.1023/a:1013374630274. Pharm Res. 2001. PMID: 11785692
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous